Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
(Sharecast News) - Analysts at ShoreCap doubled down on their recent reinitiation of coverage on AstraZeneca with a 'buy' recommendation, citing growth and pipeline prospects.
Read more
(Alliance News) - AstraZeneca PLC on Thursday shared its latest regulatory successes in a key market, winning approvals for three treatments in Japan.
Read more(Sharecast News) - AstraZeneca and MSD's Lynparza has been approved in Japan for the treatment of patients with BRCA-mutated (BRCAm), HER2-negative early breast cancer at high risk of recurrence, the companies said on Thursday.
Read more(Alliance News) - AstraZeneca PLC on Wednesday announced it will provide new safety and efficacy data on several of its cancer drugs, purporting to show longer survival for cancer patients.
Read moreAptamer Group PLC - York, England-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - For the year ended June 30, revenue is expected to more than double to GBP4.0 million from GBP1.6 million reported the prior 15-month period.
Read more(Sharecast News) - Interest rate sensitive segments of the FTSE 3500 dragged the index lower at the end of the week, as investors digested a flurry of Fed speakers overnight whose overarching message appeared to be that interest rates would remain higher for longer, although there were slight variations as to just how high.
Read more(Alliance News) - The FTSE 100 managed to outperform European counterparts on Friday due to weakness in the pound as consumer confidence in the UK fell to a record low, while attention turns to next week's Jackson Hole Symposium.
Read more(Alliance News) - London's FTSE 100 outperformed peers but was unable to stave off selling pressure in a tough session for European stocks on Friday, despite sitting just above positive territory for much of the late-morning's trade.
Read more
Aug 17 (Reuters) - Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.
Read more(Alliance News) - AstraZeneca PLC on Tuesday said its prostate cancer drug candidate Lynparza has received priority review from the US Food & Drug Administration.
Read more(Sharecast News) - Pharmaceutical company AstraZeneca said its Lynparza prostate cancer treatment application had been granted priority review in the US.
Read moreLONDON, Aug 15 (Reuters) - Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus.
Read moreAug 15 (Reuters) - European shares hovered near two-month highs on Monday as signs of a slowing Chinese economy prompted investors to turn to defensive sectors such as healthcare and consumer staples typically seen as immune to business cycles.
Read more(Alliance News) - Stocks in London struggled on Monday, but managed to end higher, even as China's central bank slashed key interest rates as a raft of data showed weakness in the world's second-largest economy.
Read moreAug 15 (Reuters) - AstraZeneca said a late-stage trial had confirmed the benefit of breast cancer drug Enhertu in patients with an advanced form of the disease who had been previously treated with another therapy.
Read more
Last checked at